Emedastine [INN] en es it fr

Emedastine [INN] Brand names, Emedastine [INN] Analogs

Emedastine [INN] Brand Names Mixture

  • No information avaliable

Emedastine [INN] Chemical_Formula


Emedastine [INN] RX_link


Emedastine [INN] fda sheet

Emedastine_[INN] FDA

Emedastine [INN] msds (material safety sheet)

Emedastine [INN] Synthesis Reference

No information avaliable

Emedastine [INN] Molecular Weight

393.436 g/mol

Emedastine [INN] Melting Point

No information avaliable

Emedastine [INN] H2O Solubility

Very slightly soluble (hydrochloride salt - maximal solubility of approximately 0.4 mg/mL occurs at a pH of approximately 2)

Emedastine [INN] State


Emedastine [INN] LogP


Emedastine [INN] Dosage Forms

Tablet (27.3 mg, 109.3 mg or 163.9 mg)

Emedastine [INN] Indication

For the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Also for use, in combination with gemcitabine, as the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Emedastine [INN] Pharmacology

Erlotinib is a Human Epidermal Growth Factor Receptor Type 1/Epidermal Growth Factor Receptor (HER1/EGFR) tyrosine kinase inhibitor.

Emedastine [INN] Absorption

Erlotinib is about 60% absorbed after oral administration and its bioavailability is substantially increased by food to almost 100%.

Emedastine [INN] side effects and Toxicity

Symptoms of overdose include diarrhea, rash, and liver transaminase elevation.

Emedastine [INN] Patient Information

Emedastine [INN] Organisms Affected

Humans and other mammals